HAE
Haemonetics
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NYSE: HAE
- PEG Ratio
HAE's PEG ratio is unavailable because the earnings growth data is negative or zero. Historical data from December 2025 indicates Haemonetics with a PEG ratio of 0.52.
HAE PEG ratio history
Haemonetics's ten years historical PEG ratio has an average of 3.04. HAE reached its maximum PEG ratio of 17.84 during the Apr 2021 quarter over the past ten years. The Dec 2022 quarter had the bottom reading at 0.12, indicating the most optimal growth-adjusted valuation.
Haemonetics PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2026 | N/A | 26.23 | -38.1% |
| 2025 | 0.44 | 18.98 | 43.5% |
| 2024 | 16.72 | 36.79 | 2.2% |
| 2023 | 0.22 | 36.45 | 167.1% |
| 2022 | N/A | 75.12 | -45.9% |
| 2021 | 17.84 | 71.36 | 4% |
| 2020 | 1.63 | 66.85 | 41.1% |
| 2019 | 3.35 | 81.76 | 24.4% |
| 2018 | 0.32 | 85.07 | 268.6% |
| 2017 | N/A | N/A | 53.2% |
| 2016 | N/A | N/A | -430.3% |
| 2015 | N/A | 133.97 | -51.5% |
| 2014 | N/A | 47.22 | -10.5% |
| 2013 | N/A | 54.82 | -42.4% |
| 2012 | N/A | 26.39 | -17% |
Haemonetics PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | N/A | 26.23 | -38.1% |
| Dec 2025 | 0.52 | 21.99 | 42.6% |
| Sep 2025 | 0.34 | 14 | 41.6% |
| Jun 2025 | 0.49 | 22.43 | 45.6% |
| Mar 2025 | 0.44 | 18.98 | 43.5% |
| Dec 2024 | 12.63 | 30.3 | 2.4% |
| Sep 2024 | N/A | 32.84 | -4% |
| Jun 2024 | N/A | 36.61 | -16% |
| Mar 2024 | 16.72 | 36.79 | 2.2% |
| Dec 2023 | 1.04 | 34.2 | 33% |
| Sep 2023 | 0.7 | 35.41 | 50.6% |
| Jul 2023 | 0.3 | 31.65 | 103.8% |
| Apr 2023 | 0.22 | 36.45 | 167.1% |
| Dec 2022 | 0.12 | 41.84 | 337.2% |
| Oct 2022 | 0.25 | 44.07 | 175.4% |
HAE average PEG ratio chart
PEG comparison
HAE EPS growth
HAE Price vs fair value
HAE PEG vs peers
| Stock name | PEG ratio | Market cap |
|---|---|---|
| SYK Stryker Corp | 2.29 | $126.6B |
| TMO Thermo Fisher Scientific Inc | 4.73 | $211.18B |
| MDT Medtronic plc | 6.72 | $106.51B |
| BDX Becton Dickinson & Co | N/A | $43.08B |
| CERS Cerus Corp | N/A | $587.08M |
| BAX Baxter International Inc | N/A | $11.57B |
| JNJ Johnson & Johnson | N/A | $634.77B |
| HAE Haemonetics Corp | N/A | $3.58B |
Frequently asked questions
What is Haemonetics's PEG ratio?
HAE's PEG ratio is unavailable because EPS growth data is negative or not present.
What is the 3-year average PEG ratio for Haemonetics (HAE)?
Over the last 3 years, HAE's PEG ratio has settled near 4.11.
What is the 5-year average PEG ratio for Haemonetics (HAE)?
Over the last 5 years, HAE's PEG ratio has settled near 3.6.
What is the highest PEG ratio for HAE?
HAE's PEG ratio peaked at 17.84 during the Apr 2021 quarter - the highest in ten years.
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.